# FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00383565** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Mantle Cell Lymphoma

## Interventions

- **DRUG:** romidepsin

## Key facts

- **NCT ID:** NCT00383565
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383565, "FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00383565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*